Haematological Malignancy Clinical Trial
Official title:
Kinectics of Donor-specific Anti-HLA Antibody After HLA-incompatible Allogeneic Haematopoietic Stem Cell Transplantation
Donor specific anti-HLA antibody (DSA) is closely related not only to primary graft rejection (GR) after HLA-incompatible transplantation, but also to the occurrence of primary PGF. Desensitisation therapy can reduce the level of DSA in patients and decrease the incidence of PGF after transplantation. However, most studies at home and abroad have focused on DSA levels in recipients before transplantation, risk factors and their effects on prognosis. Very few studies have focused on the rate of DSA positivity and its risk factors after transplantation. Therefore, this project aims to clarify the rate of DSA positivity after HLA-incompatible Allo-HSCT and reveal the influencing factors of post-transplantation DSA positivity with the help of a prospective, registry-based clinical cohort of HLA-incompatible transplant recipients, in order to provide a basis for the prevention and treatment of DSA-induced graft rejection or PGF.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03978312 -
Nutrition Health Literacy of Cancer Patients and Their Support Networks.
|
||
Recruiting |
NCT03750994 -
Economic Evaluation of Innovative Molecular Analyses in Onco-haematology
|
||
Recruiting |
NCT04397705 -
Remote Monitoring of Cancer Patients With Suspected Covid-19
|
Phase 1 | |
Recruiting |
NCT05678621 -
Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Immunoglobulin Stopping or Extension
|
Phase 2/Phase 3 | |
Recruiting |
NCT05203809 -
Continuous Temperature Monitoring for tHe Early Recognition of Febrile Neutropenia in Haematological MALignancies
|
||
Active, not recruiting |
NCT03146468 -
Nivolumab for Relapsed or Residual Haematological Malignancies After Allogeneic Stem Cell Transplantation
|
Phase 2 | |
Recruiting |
NCT05298930 -
Feasibility Study to Assess an Adapted Physical Activity Program in Children, Adolescents and Young Adults Requiring Hematopoietic Stem Cell Transplantation
|
N/A | |
Recruiting |
NCT05786716 -
DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Teenage/Young Adult and Paediatric Patients With Cancers With HER2 Amplification or Activating Mutations
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT04673305 -
Cognitive Status Assessment In Elderly Patients With Active Treatment For Haematological Malignancies
|
N/A | |
Recruiting |
NCT05768178 -
DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.
|
Phase 2/Phase 3 | |
Recruiting |
NCT05722886 -
DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol
|
Phase 2/Phase 3 | |
Completed |
NCT03855969 -
Central Venous Access Device Removal in Cancer Patients
|
||
Recruiting |
NCT04174053 -
Concordance Between 2 Means of Temperature Measure in Neutropenic Patients Hospitalized in Intensive Hematology Care Units
|
N/A | |
Recruiting |
NCT05770544 -
DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Teenage/Young Adults and Paediatric Patients With ROS1 Gene Fusion-positive Cancers.
|
Phase 2/Phase 3 | |
Recruiting |
NCT05379738 -
Impact of Adapted Physical Activity on Patient's Recovery Following Allogeneic Stem Cell Transplantation for Hematological Malignancy
|
N/A | |
Completed |
NCT04236063 -
Rehabilitation Needs of the Malaysian Haematological Cancer Survivors
|
||
Recruiting |
NCT05695638 -
Proseq Cancer: Genomic Profiling in Patients With Incurable Cancer in Search for Targeted Treatment
|
||
Recruiting |
NCT04298892 -
Integrated Multiomics and Multilevel Characterization of Haematological Disorders and Malignancies
|
||
Withdrawn |
NCT03688789 -
Hématologie Adulte Prevalence of Adrenal Insufficiency Post-chemotherapy Adrenocorticotropia in Adult Hematology
|
N/A | |
Withdrawn |
NCT04331483 -
A Study to Assess a Physical Activity Program in Children, Adolescents and Young Adults Requiring Hematopoietic Stem Cell Allografts
|
N/A |